Ibogaine vs Suboxone: Questions to Ask First

People who search for ibogaine vs suboxone are usually already taking Suboxone, or love someone who is. Some feel stable on it and wonder whether there is a way to stop needing it. Others are tired of daily dosing, pharmacy visits or the sense that they have swapped one dependence for another.

Comparing the two on paper only goes so far. The harder questions come up at the point where one would end and the other begin.

This article does not try to settle which is better. A broad comparison of how each works, its evidence and its costs is covered in our ibogaine vs suboxone overview. Here the focus is narrower: the specific medical questions a person on buprenorphine should be able to get clear answers to before going anywhere near ibogaine.

How do ibogaine and Suboxone differ as treatments?

Suboxone combines buprenorphine, a partial opioid agonist, with naloxone. It is approved by the FDA for opioid use disorder and is usually taken daily over months or years. It reduces cravings and withdrawal and, for many people, makes ordinary life possible again. Buprenorphine treatment is supported by a large body of research and is a mainstream treatment recommended by U.S. agencies including SAMHSA.

Ibogaine is a different kind of substance. It is a psychoactive alkaloid from the root bark of an African shrub, usually given as a single large dose under observation. If you want the basics of its chemistry and effects, start with what is ibogaine. People who have taken it often report fewer withdrawal symptoms afterwards, and some describe a shift in how they relate to cravings.

The evidence behind the two is not comparable. A 2022 systematic review by Köck and colleagues in the Journal of Substance Abuse Treatment found that research on ibogaine for opioid use disorder comes mainly from observational studies and case series, and that controlled trials are still needed.

Ibogaine is not approved for any use in the United States, where it is a Schedule I substance. Mexico has not scheduled it, which means it is unregulated there, not approved. A clinic in Mexico may hold a health establishment license, but that license is not an approval of ibogaine.

The risk that changes the comparison

Ibogaine affects the heart's electrical rhythm by lengthening the QT interval. People have died during or after ibogaine treatment, in medical clinics as well as in informal settings. Heart rhythm problems are suspected as the cause in many of those deaths, and no one knows how often they happen.

In a small hospital study published in Addiction in 2022, Knuijver and colleagues reported that monitored patients reached dangerous QT intervals. Monitoring can help staff spot a dangerous rhythm early enough to treat it. It does not prevent one, and it can miss one.

Why can't you take ibogaine while on Suboxone?

This is where the two treatments collide. Buprenorphine is long-acting and binds tightly to opioid receptors. Ibogaine programs generally want it out of the body before dosing, and getting there is neither quick nor simple.

How long buprenorphine takes to clear depends on its form and dose. Daily sublingual films and tablets behave differently from a long-acting monthly injection, which can stay detectable for a year or more. Routine urine screens can miss buprenorphine, so a negative result on a standard panel does not mean it has gone. Ask any clinic exactly how it confirms that buprenorphine has cleared.

In the Knuijver hospital study, patients were moved onto morphine under medical monitoring before dosing. Methadone takes days to clear and itself prolongs the QT interval, and buprenorphine is long-acting and binds tightly, so the researchers used a short-acting opioid instead. That was a research protocol in a hospital. It is not an instruction and not a standard protocol for anyone to follow.

What the law means for a transition

In the United States, no prescriber can lawfully write a prescription for morphine, methadone or another Schedule II opioid to treat opioid use disorder. Buprenorphine is Schedule III, which is why it can be prescribed. Methadone for addiction normally comes only from a certified opioid treatment program, and such programs may not use morphine outside a research protocol.

That has practical consequences. Your own prescriber or program will not arrange a switch to morphine for you, and nothing about a transition should be arranged at home. Any switch before dosing is done by the treating clinic's physicians, where the treatment takes place.

Never bridge with opioids from any other source. Pills or powders bought outside a pharmacy may contain fentanyl, and a negative fentanyl test strip does not make a drug safe.

Stopping buprenorphine or methadone carries its own overdose risk, and it is done with a prescriber, never alone. Nothing in this article is a reason to stop, bridge or change either one.

What should you ask a clinic before ibogaine?

Any clinic worth considering should answer these questions plainly, in writing if you ask. Vague answers are themselves an answer.

About buprenorphine and other opioids

• How many days before dosing must buprenorphine stop, and what will I take in the meantime?
• How do you confirm buprenorphine has cleared, given that routine urine screens can miss it?
• If I have had a long-acting buprenorphine injection, how do you handle that?
• Who manages any transition medication, and is it done on site by your physicians?
• Have you treated people who have used fentanyl? No published ibogaine study has enrolled a fentanyl-using population, so any answer is based on a clinic's own experience, not on trial evidence.

About the heart and the body

• What cardiac screening do you do, and what ECG findings rule a person out?
• Are potassium and magnesium checked and corrected before dosing, and again after vomiting?
• Do you give magnesium? It is a reasonable precaution, but no study has shown it prevents arrhythmia.
• What monitoring runs during and after dosing, for how long, and who is watching it?
• How far is the nearest hospital that can manage a cardiac emergency, and how would I get there?

About other medicines and substances

• Which of my medications interact with ibogaine? It is cleared by a liver enzyme that varies from person to person, and some medicines raise its level. Some antidepressants block that enzyme and take weeks, not days, to wash out. Stopping an antidepressant has its own risks and is done only with the prescriber who prescribed it.
• If I drink heavily or use benzodiazepines, how is that stabilised first? Withdrawal seizures appear in the fatality reports.

What Suboxone does that ibogaine does not

Buprenorphine has a ceiling effect on breathing, which is part of why it is considered a safer opioid. That ceiling does not hold when it is combined with alcohol, benzodiazepines or other sedatives. Its own effect on the QT interval is small but not zero. How it combines with ibogaine's effect is not known, which is one more reason clinics want it cleared.

What happens to opioid tolerance after ibogaine?

This is the single most important safety point for anyone leaving treatment. After ibogaine, opioid tolerance falls by an amount no one can predict, so a dose a person used before can be a fatal overdose. Opioids may also act more strongly than expected after treatment.

Before leaving any clinic:

• Leave with naloxone, and make sure the people around you know how to use it.
• If someone may have overdosed, give naloxone and call emergency services straight away. Naloxone is still given when xylazine may be present.
• Settle with the treating physician whether and when buprenorphine or methadone would restart, and who would provide it. Methadone for addiction normally comes only from a certified program, and it prolongs the QT interval.

The first week and beyond

The QT interval commonly stays long past the first day, and in reported cases for more than a week. Travel should follow a normal ECG, not a set number of days. Fainting, a racing or irregular heartbeat or a seizure is an emergency at any time, and the risk lasts at least through the first week and until an ECG is normal. Until then, no new medicine should be started, anti-nausea drugs included, without asking a prescriber who knows about the ibogaine whether it affects the QT interval.

Expect to need help walking for at least a day after dosing. Plan for someone to stay with you, and for aftercare that continues once the acute effects have passed.

Questions for your own prescriber

Your current prescriber knows your history and is worth talking to before you decide anything. You do not need their permission to ask questions, and an honest conversation often surfaces things a clinic intake form would miss. Useful things to raise include:

• Your recent ECG results, if you have had one, and any history of fainting, palpitations or heart problems in you or your close relatives.
• A complete, current list of every medicine and supplement you take, with doses, to share with any clinic you consider.
• What restarting buprenorphine would involve if you stopped it and later wanted to go back.
• Getting naloxone for yourself and showing the people you live with how to use it.

Keep copies of your records. A clinic that asks for them, and reads them carefully, is showing you something about how it works.

Weighing ibogaine vs Suboxone honestly

For many people, Suboxone is working, and staying on it is a reasonable and often protective choice. For others, the wish to stop is real and worth discussing with a prescriber who will take it seriously. The ibogaine vs Suboxone decision comes down to the hard medical details: how buprenorphine would be cleared, who would manage that, what the heart risks are and what happens to tolerance afterwards.

If you are still weighing ibogaine vs Suboxone, the Ibogaine Treatment Guide collects plain-language pages on safety, screening, costs and aftercare. Bring these questions to any conversation with a clinic, and to your own prescriber before anything changes.